We believe that JAK2 mutation testing will rapidly become a frontline test for individuals with a suspected diagnosis of an MPD and the same genetic event can play a role in the pathogenesis of a wide spectrum of myeloid and lymphoid malignancies. The gene discussed is JAK2; the disease is myeloproliferative disorder.